Message from the Chairman of Board of Directors
This is an era of innovation!
This is an era of change!
Looking back to the past, BPL has always taken innovation as its objective, adhered to its responsibility to improve people’s health and benefit more patients. BPL has been focused on the research and development humanized monoclonal antibodies for the past 21 years, and BPL is the first in China to establish the humanization platform of antibodies, design and install the world-advanced production train of perfusion process, and to develop China’s first monoclonal antibody Nimotuzumab (which takes EGFR as its target)
Looking into the future, BPL will keep pace with the times, accelerate research and development, continuously improves its production capacity and make vigorous academic promotion for its products. Besides, BPL will invest more in attracting and cultivating talents to maintain its competitiveness and to realize sustainable development. It is believed that BPL will provide more safe and effective medicines for patients with cancer and auto-immune diseases.
We sincerely look forward to extensive and in-depth exchanges and cooperation with all sectors of society to create a bright future for China's biopharmaceutical industry!
----- By Mr. Bai Xianhong Chairman of Board of Directors
Biotech pharmaceutical co., Ltd